Advancing Research in Biotechnology and Space Medicine
RDI – Research Discovery Innovation develops solutions in biotechnology, medical research, and radiation protection. Our work focuses on advancing cancer treatments and enhancing DNA repair technologies for applications in both medicine and space research.
Through evidence-based research and interdisciplinary collaboration, we translate scientific discoveries into practical applications. Our goal is to optimize treatments, reduce side effects, and develop technologies suited for both clinical and extreme environments.
Learn more about our research areas and technological solutions.
Radiation Therapy
BP-C2 Applications
Oncology Research
BP-C1 in Cancer Treatment
Space
BP-C2 in Space Research
BP-C2 is being explored to enhance radiation therapy, reducing side effects and improving patient recovery. It protects healthy tissue from radiation damage, reducing toxicity while maintaining treatment efficacy.
BP-C1 is a novel platinum-based chemotherapy for metastatic cancer treatment, including breast and pancreatic cancers. Its unique formulation offers reduced toxicity and improved patient compliance.
.
BP-C2 supports DNA repair and radiation protection, offering potential applications in space medicine. It could help safeguard astronauts from cosmic radiation during long-duration space missions.
Fab4Future
A Biofabrication Toolbox for Sustainable Living Materials
PULSE Project
Bioprinting for Space Research and Medicine
Aging Support
BP-C3
Fab4Future is an interdisciplinary research initiative focused on developing a biofabrication toolbox for the next generation of sustainable living materials in the life sciences. The project integrates advanced fabrication methods and AI-driven technologies to enable tailored and scalable production of functional biomaterials.
PULSE is an EU-funded research initiative dedicated to advancing bioprinting technology using magnetic and acoustic levitation. The project focuses on creating precise 3D heart models to study how space conditions and radiation affect cardiovascular health.
BP-C3 is an oral, science-backed therapeutic designed to support healthy aging, vitality, and systemic resilience in both cancer patients and aging populations. Developed by RDI using the proprietary BP-Cx1 polyphenolic platform, BP-C3 addresses core mechanisms of aging and treatment-related fatigue — making it a powerful tool in both oncology support and the broader longevity market.